- Home
- IRMD vs ORIC Comparison
IRMD vs ORIC Comparison
Compare IRMD & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRMD
- ORIC
- Stock Information
- Founded
- IRMD 1992
- ORIC 2014
- Country
- IRMD United States
- ORIC United States
- Employees
- IRMD N/A
- ORIC N/A
- Industry
- IRMD Medical/Dental Instruments
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- IRMD Health Care
- ORIC Health Care
- Exchange
- IRMD Nasdaq
- ORIC Nasdaq
- Market Cap
- IRMD 756.5M
- ORIC 362.9M
- IPO Year
- IRMD 2014
- ORIC 2020
- Fundamental
- Price
- IRMD $58.02
- ORIC $11.10
- Analyst Decision
- IRMD Strong Buy
- ORIC Strong Buy
- Analyst Count
- IRMD 1
- ORIC 9
- Target Price
- IRMD $72.00
- ORIC $18.29
- AVG Volume (30 Days)
- IRMD 67.2K
- ORIC 949.2K
- Earning Date
- IRMD 07-31-2025
- ORIC 08-11-2025
- Dividend Yield
- IRMD 1.14%
- ORIC N/A
- EPS Growth
- IRMD 10.72
- ORIC N/A
- EPS
- IRMD 1.55
- ORIC N/A
- Revenue
- IRMD $75,154,639.00
- ORIC N/A
- Revenue This Year
- IRMD $10.62
- ORIC N/A
- Revenue Next Year
- IRMD $9.69
- ORIC N/A
- P/E Ratio
- IRMD $38.37
- ORIC N/A
- Revenue Growth
- IRMD 11.04
- ORIC N/A
- 52 Week Low
- IRMD $42.34
- ORIC $3.90
- 52 Week High
- IRMD $63.29
- ORIC $14.67
- Technical
- Relative Strength Index (RSI)
- IRMD 46.18
- ORIC 66.82
- Support Level
- IRMD $58.44
- ORIC $10.42
- Resistance Level
- IRMD $60.85
- ORIC $11.50
- Average True Range (ATR)
- IRMD 1.62
- ORIC 0.62
- MACD
- IRMD -0.40
- ORIC -0.03
- Stochastic Oscillator
- IRMD 8.87
- ORIC 83.30
About IRMD iRadimed Corporation
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.